Filing Flows

Filing Flows › Companies › Bioventus › Cash flow

Bioventus cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$20.3M in Q3 2026 · $85.0M over twelve months

Operating cash flow$20.7M
Capital spending−$334K
Free cash flow+$20.3M
Cash / net income3.0×
Cash conversion cycle206 days

Analysis

In Q3 2026, Bioventus generated $20.7M of operating cash flow and spent $334K on capital projects, leaving free cash flow of $20.3M.

Over the twelve months to Sep 26, 2026, operating cash flow was $87.4M; the largest uses were other financing ($68.3M), net borrowing (+) / repaid (−) ($25.9M), other investing ($3.0M); besides operations, cash came from shares issued ($2.9M); the cash balance fell by $11.5M.

Operating cash flow was $20.7M against net income of $6.9M — 3.0× profit, cash ran ahead of reported earnings. The largest differences: depreciation & amortization +$10.3M, stock-based pay +$4.8M, payables +$4.1M.

Its cash conversion cycle was 206 days (receivables 88 + inventory 164 − payables 46).

Free cash flow

Bioventus: free cash flow by quarterBioventus: free cash flow by quarter$18.7MQ4 2024−$20.2MQ1 2025$25.3MQ2 2025$29.6MQ3 2025$37.4MQ4 2025$8.4MQ1 2026$18.9MQ2 2026$20.3MQ3 2026
Operating cash flow less capital spending.
Bioventus: operating cash flow against capital spendingBioventus: operating cash flow against capital spendingOperating cash flowCapital spending$19.3M$574KQ4 2024−$19.3M$826KQ1 2025$25.9M$683KQ2 2025$30.1M$473KQ3 2025$38.0M$580KQ4 2025$8.9M$574KQ1 2026$19.9M$960KQ2 2026$20.7M$334KQ3 2026
Latest (Q3 2026): Operating cash flow $20.7M, Capital spending $334K.

Capital allocation, year by year

Bioventus: where the cash came from (up) and went (down), by fiscal yearBioventus: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingAcquisitionsFY2021: Operating cash flow $23.0MFY2021: Net borrowing −$37KFY2021: Shares issued $2.1MFY2021: Capital spending −$13.5MFY2021: Acquisitions −$263M$25.1MFY2021FY2022: Operating cash flow −$13.5MFY2022: Net borrowing −$53KFY2022: Shares issued $5.8MFY2022: Capital spending −$1.5M$5.8MFY2022FY2023: Operating cash flow $15.3MFY2023: Net borrowing $14.5MFY2023: Shares issued $778KFY2023: Asset sales $34.7MFY2023: Capital spending −$7.4M$65.3MFY2023FY2024: Operating cash flow $38.8MFY2024: Net borrowing −$15.8MFY2024: Shares issued $2.4MFY2024: Asset sales $24.7MFY2024: Capital spending −$1.0M$65.9MFY2024FY2025: Operating cash flow $74.7MFY2025: Net borrowing −$822KFY2025: Shares issued $2.1MFY2025: Capital spending −$2.6M$76.7MFY2025
Over these 5 years operating cash flow totalled $138M; the largest uses were acquisitions ($263M) and capital spending ($25.9M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$30.7M
Debt$230M
Net debt$199M
Due within a year$18.8M

Bioventus funds itself: free cash flow was $85.0M over the last twelve months, and $30.7M of cash and investments stands against $230M of debt ($18.8M due within a year, 1.6× covered by cash).

Where the cash came from and went

Bioventus: sources (+) and uses (−) of cash, Q3 2026Bioventus: sources (+) and uses (−) of cash, Q3 2026Operating cash flow$20.7MOther financing−$18.8MOther investing−$1.5MShares issued$1.4MCash drawn (+) / kept (−)−$1.3MCapital spending−$334KNet borrowing (+) / repaid (−)−$227KTaxes on employees’ shares−$19KExchange rates$11K
Bioventus: sources (+) and uses (−) of cash, TTM to Q3 2026Bioventus: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow$87.4MOther financing−$68.3MNet borrowing (+) / repaid (−)−$25.9MCash drawn (+) / kept (−)$11.5MOther investing−$3.0MShares issued$2.9MCapital spending−$2.4MTaxes on employees’ shares−$1.4MExchange rates−$834K

From profit to cash

Bioventus: net income to operating cash flow, Q3 2026Bioventus: net income to operating cash flow, Q3 2026Net income$6.9MDepreciation & amortization$10.3MStock-based pay$4.8MDeferred taxes−$487KReceivables$152KInventory−$3.5MPayables$4.1MOther operating capital−$1.7MOperating cash flow$20.7M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 20268816446206
Q2 20267715642191
Q1 20268217437219
Q4 20257817336214
Q3 20258619752232
Q2 20257719043224
Q1 20258720146242
Q4 20247616837207

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$20.7M−$334K−$227K$1.4M−$1.3M$20.3M
Q2 2026$19.9M−$960K−$226K$853K$6.4M$18.9M
Q1 2026$8.9M−$574K−$220K$120K$15.4M$8.4M
Q4 2025$38.0M−$580K−$25.2M$511K−$9.1M$37.4M
Q3 2025$30.1M−$473K$19.8M$96K−$9.3M$29.6M
Q2 2025$25.9M−$683K−$5.2M$1.3M−$10.1M$25.3M
Q1 2025−$19.3M−$826K—$150K$18.8M−$20.2M
Q4 2024$19.3M−$574K−$15.2M$1.1M$1.5M$18.7M

Bioventus: income statement and cash flow

Bioventus, Q3 2026: revenue $142M (+3% year over year), operating margin 6.8%. The chart follows the revenue to costs, profit and cash.

Bioventus: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.